Parsortix platform shown to be compatible with the Roche BenchMark ULTRA automated staining system, with initial study of three key drug targets: HER2 (breast), TROP2 (lung) and PSMA (prostate) Roche ...
VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it has ...
Explore the role of patient-derived biology in enhancing antibody-drug conjugates for more effective cancer treatment.
SOUTH SAN FRANCISCO, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site-specific and novel-format ...
STRO-004 (tissue factor ADC) preclinical data has demonstrated greater anti-tumor activity and lower toxicity compared to a benchmark tissue factor ADC Preclinical models highlight potent anti-tumor ...
Parsortix platform shown to be compatible with the Roche BenchMark ULTRA automated staining system, with initial study of three key drug targets: HER2 (breast), TROP2 (lung) and PSMA (prostate) ...
WESTBURY, N.Y.--(BUSINESS WIRE)--BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced it will attend and sponsor the 8th Annual ...
GUILFORD, SURREY AND PLYMOUTH MEETING, PA / ACCESS Newswire / November 5, 2025 / CELLBXHEALTH plc (AIM:CLBX)(OTCQX:ANPCY), a global leader in circulating tumour cell (CTC) intelligence, announces the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback